Study of Glucarpidase (CPG2) for the Management of Patients With Delayed Methotrexate Clearance
Status:
Completed
Trial end date:
2003-06-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of glucarpidase in patients with impaired methotrexate
(MTX) clearance owing to MTX-induced renal failure following high-dose MTX therapy, or with
intrathecal MTX overdose.